Literature DB >> 16702803

Pyomyositis with hepatic and perinephric abscesses caused by Candida albicans in a diabetic nephropathy patient.

Shih-Hung Tsai1, Yi-Jen Peng, Ning-Chi Wang.   

Abstract

Both disseminated candidiasis and pyomyositis are rare and mainly encountered in severely immunocompromised hosts. To our knowledge, Candida albicans related pyomyositis with formation of multiple visceral abscesses in a diabetic nephropathy patient has never previously been reported. A 47-year-old man with diabetic nephropathy and alcoholic liver disease developed disseminated candidiasis, with the initial presentation of pyomyositis. Debridement was performed and intravenous fluconazole commenced. Despite development of a single hepatic and multiple perinephric abscesses, the patient made a full recovery after completion of a 12-week course of intravenous fluconazole therapy. Candida species should be considered a potential pathogen in patients with predisposing factors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16702803     DOI: 10.1097/00000441-200605000-00013

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  5 in total

Review 1.  Bacterial, fungal, parasitic, and viral myositis.

Authors:  Nancy F Crum-Cianflone
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

2.  Multimodality imaging of Candida tropicalis myositis.

Authors:  Daniel M Schwartz; Elaine R Morgan
Journal:  Pediatr Radiol       Date:  2007-12-20

3.  Nonbacterial myositis.

Authors:  Nancy F Crum-Cianflone
Journal:  Curr Infect Dis Rep       Date:  2010-09       Impact factor: 3.725

4.  Treatment of fungal myositis with intra-lesional and intravenous itraconazole: a case report.

Authors:  Xiao-Ji Lin; Rong-Xin Yao; Mu-Qing He; Bao-Ling Zhu; Wen-Jian Guo
Journal:  J Med Case Rep       Date:  2013-05-19

Review 5.  Infective myositis.

Authors:  Gayathri Narayanappa; Bevinahalli Nanjegowda Nandeesh
Journal:  Brain Pathol       Date:  2021-05       Impact factor: 6.508

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.